tiprankstipranks
Advertisement
Advertisement

SVRA Stock Latest News

Savara presents poster at ATS 2026 International Conference on IMPALA-2
The FlySavara presents poster at ATS 2026 International Conference on IMPALA-2
16d ago
SVRA
Savara reports Q1 EPS (15c), consensus (14c)
PremiumThe Fly
Savara reports Q1 EPS (15c), consensus (14c)
24d ago
SVRA
Savara assumed with an Outperform at Oppenheimer
PremiumThe Fly
Savara assumed with an Outperform at Oppenheimer
1M ago
SVRA
Savara says FDA extended review for Molgramostim BLA
PremiumThe Fly
Savara says FDA extended review for Molgramostim BLA
2M ago
SVRA
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
PremiumRatings
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
2M ago
SVRA
Savara announces MHRA accepted submission of Molbreevi MAA
PremiumThe FlySavara announces MHRA accepted submission of Molbreevi MAA
2M ago
SVRA
Savara announces EMA validation of MAA for MOLBREEVI
Premium
The Fly
Savara announces EMA validation of MAA for MOLBREEVI
2M ago
SVRA
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
Premium
Ratings
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
3M ago
SVRA
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
PremiumRatings
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
3M ago
SVRA
Midday Fly By: Adobe CEO to step down, Meta delays ‘Avocado’ AI model launch
PremiumThe Fly
Midday Fly By: Adobe CEO to step down, Meta delays ‘Avocado’ AI model launch
3M ago
BX
MS
Savara Signs Long-Term Lease for New Headquarters
PremiumCompany Announcements
Savara Signs Long-Term Lease for New Headquarters
3M ago
8K
SVRA
Savara reports Q4 EPS (13c), consensus (12c)
PremiumThe Fly
Savara reports Q4 EPS (13c), consensus (12c)
3M ago
SVRA
Savara announces receipt of Day 74 Letter from FDA
PremiumThe FlySavara announces receipt of Day 74 Letter from FDA
3M ago
SVRA
Savara says FDA files BLA for Molbreevi
Premium
The Fly
Savara says FDA files BLA for Molbreevi
3M ago
SVRA
Savara announces BLA for Molbreevi filed for review by FDA
Premium
The Fly
Savara announces BLA for Molbreevi filed for review by FDA
3M ago
SVRA
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
PremiumCompany Announcements
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
4M ago
SVRA
Savara Enters New Material Definitive Agreement and Obligation
PremiumCompany Announcements
Savara Enters New Material Definitive Agreement and Obligation
4M ago
8K
SVRA
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
PremiumRatings
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
5M ago
SVRA
Savara Highlights Autoimmune PAP Burden in Updated Presentation
PremiumCompany Announcements
Savara Highlights Autoimmune PAP Burden in Updated Presentation
5M ago
8K
SVRA
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
PremiumRatingsSavara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
5M ago
SVRA
Savara price target raised to $10 from $8 at H.C. Wainwright
Premium
The Fly
Savara price target raised to $10 from $8 at H.C. Wainwright
5M ago
SVRA
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
Premium
Ratings
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
5M ago
SVRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >